Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.O)

REGN.O on Nasdaq

310.83USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$310.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
776,275
52-wk High
$442.00
52-wk Low
$295.27

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $33,484.91
Shares Outstanding(Mil.): 107.73
Dividend: --
Yield (%): --

Financials

  REGN.O Industry Sector
P/E (TTM): 15.13 104.93 37.25
EPS (TTM): 20.54 -- --
ROI: 24.26 7.73 12.15
ROE: 29.47 8.25 16.99

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Apr 26 2019

UPDATE 1-U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

April 26 The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Apr 26 2019

U.S. FDA approves expanded label for Regeneron's cholesterol drug

April 26 The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Apr 26 2019

Genzyme and vaccines push up Sanofi's first quarter results

PARIS Sanofi upheld a long-awaited return to growth on Friday with higher profits and revenues for the first quarter, once again led by a stellar sales increase at its rare diseases Genzyme unit.

Apr 26 2019

UPDATE 1-Genzyme and vaccines push up Sanofi's Q1 results

* Pressure remains on diabetes and cardiovascular (Adds details)

Apr 26 2019

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Apr 08 2019

UPDATE 2-Regeneron forays into gene-silencing therapies with Alnylam tie-up

April 8 Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Apr 08 2019

Alnylam, Regeneron to partner for RNAi treatments

April 8 Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.

Apr 08 2019

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Mar 11 2019

UPDATE 2-Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

March 11 The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Mar 11 2019

Earnings vs. Estimates